Universal Beteiligungs und Servicegesellschaft mbH Acquires 111,941 Shares of Organon & Co. $OGN

Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in shares of Organon & Co. (NYSE:OGN) by 27.1% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 525,423 shares of the company’s stock after purchasing an additional 111,941 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Organon & Co. were worth $3,767,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Organon & Co. by 11.3% in the 3rd quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock worth $383,715,000 after purchasing an additional 3,650,860 shares in the last quarter. State Street Corp increased its holdings in Organon & Co. by 6.0% in the 2nd quarter. State Street Corp now owns 9,520,594 shares of the company’s stock worth $92,159,000 after purchasing an additional 540,478 shares in the last quarter. AQR Capital Management LLC increased its holdings in Organon & Co. by 28.3% in the 3rd quarter. AQR Capital Management LLC now owns 4,176,144 shares of the company’s stock worth $43,641,000 after purchasing an additional 921,260 shares in the last quarter. Gotham Asset Management LLC increased its holdings in Organon & Co. by 37.2% in the 3rd quarter. Gotham Asset Management LLC now owns 3,713,204 shares of the company’s stock worth $39,657,000 after purchasing an additional 1,007,691 shares in the last quarter. Finally, Kahn Brothers Group Inc. increased its holdings in Organon & Co. by 3.6% in the 3rd quarter. Kahn Brothers Group Inc. now owns 3,616,845 shares of the company’s stock worth $38,628,000 after purchasing an additional 126,695 shares in the last quarter. Institutional investors and hedge funds own 77.43% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Zacks Research raised Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 14th. Barclays upped their target price on Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a report on Tuesday, February 24th. Wall Street Zen cut Organon & Co. from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Piper Sandler raised Organon & Co. from an “underweight” rating to a “neutral” rating and upped their target price for the stock from $5.00 to $14.00 in a report on Tuesday. Finally, BNP Paribas Exane reaffirmed a “neutral” rating and issued a $14.00 target price (up from $12.00) on shares of Organon & Co. in a report on Wednesday. Four research analysts have rated the stock with a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, Organon & Co. currently has a consensus rating of “Reduce” and an average price target of $11.40.

Trending Headlines about Organon & Co.

Here are the key news stories impacting Organon & Co. this week:

• Positive Sentiment: Sun Pharma deal and cash consideration provide a clear floor (shareholders to receive $14.00 per share), lifting M&A bidders’ enthusiasm and pushing the stock to 52-week highs. Organon & Co. (OGN) Soars to 52-Week High on $11.75-Billion Sun Merger
• Positive Sentiment: Piper Sandler upgraded OGN from underweight to neutral and set a $14.00 price target, signaling dealer support for the transaction price and narrowing downside risk. Piper Sandler upgrade
• Neutral Sentiment: Organon canceled its Q1 earnings call because of the announced agreement with Sun Pharma — a procedural step reflecting the pending deal rather than new operational news. Organon Cancels First Quarter Earnings Call
• Neutral Sentiment: BNP Paribas Exane reaffirmed a neutral rating and raised its price target to $14.00 (up from $12.00), aligning the street around the deal price while stopping short of a buy endorsement. BNP Paribas Exane reaffirmation
• Negative Sentiment: Law firms (Kahn Swick & Foti and Halper Sadeh) have launched investigations into whether the $14.00 cash price and the sale process are fair to shareholders — these inquiries can lead to litigation, potential delays, or renegotiation. Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon Co. – OGN
• Negative Sentiment: BNP Paribas Exane previously moved OGN from strong?buy to hold (coverage adjustment), signaling reduced enthusiasm from a formerly bullish analyst and potentially limiting further upside absent a competing bidder or higher offer. Analyst downgrade

Organon & Co. Trading Up 0.1%

Shares of OGN stock opened at $13.34 on Thursday. The stock has a market cap of $3.50 billion, a price-to-earnings ratio of 18.79, a PEG ratio of 1.22 and a beta of 0.67. The stock has a 50-day moving average of $7.57 and a 200-day moving average of $7.72. The company has a current ratio of 1.82, a quick ratio of 1.23 and a debt-to-equity ratio of 11.47. Organon & Co. has a 1-year low of $5.69 and a 1-year high of $13.38.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, February 12th. The company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $0.73 by ($0.10). The company had revenue of $1.51 billion during the quarter, compared to analyst estimates of $1.52 billion. Organon & Co. had a net margin of 3.01% and a return on equity of 122.01%. The company’s quarterly revenue was down 5.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.90 EPS. On average, equities research analysts forecast that Organon & Co. will post 3.23 earnings per share for the current year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 12th. Stockholders of record on Monday, February 23rd were paid a $0.02 dividend. The ex-dividend date of this dividend was Monday, February 23rd. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. Organon & Co.’s dividend payout ratio is presently 11.27%.

Organon & Co. Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.